245 related articles for article (PubMed ID: 31467066)
21. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
[TBL] [Abstract][Full Text] [Related]
22. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
23. Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia.
Cornes P; Gascon P; Chan S; Hameed K; Mitchell CR; Field P; Latymer M; Arantes LH
Adv Ther; 2018 Nov; 35(11):1816-1829. PubMed ID: 30298233
[TBL] [Abstract][Full Text] [Related]
24. A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative.
Leon Rapoport B; Garcia-Morillo M; Font C; Samoon Z; Jabbar AA; Kourie HR; Kayumba A; Esposito F; Popescu RA; García-Gómez J; Heyman L; Smit T; Krendyukov A; Mathieson N; Cooksley T; Anderson R; Klastersky J
Support Care Cancer; 2023 Oct; 31(12):628. PubMed ID: 37828258
[TBL] [Abstract][Full Text] [Related]
25. Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.
Li S; Liu J; Guo H; Gawade PL; Kim C; Bensink ME; Chandler D
Support Care Cancer; 2020 Jun; 28(6):2637-2649. PubMed ID: 31624920
[TBL] [Abstract][Full Text] [Related]
26. Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region.
Trotta F; Mayer F; Mecozzi A; Amato L; Addis A
BioDrugs; 2017 Apr; 31(2):117-124. PubMed ID: 28353170
[TBL] [Abstract][Full Text] [Related]
27. A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF).
Huang X; Li S; Shi W; Wang Y; Wan X; He J; Xu Y; Zhang W; Shi X; Chen R; Xu L; Zha X; Wang J
Br J Clin Pharmacol; 2023 Jan; 89(1):372-379. PubMed ID: 36001055
[TBL] [Abstract][Full Text] [Related]
28. Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature.
Hoshina H; Takei H
BMC Cancer; 2019 Dec; 19(1):1217. PubMed ID: 31842789
[TBL] [Abstract][Full Text] [Related]
29. Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years.
Edelsberg J; Weycker D; Bensink M; Bowers C; Lyman GH
Curr Med Res Opin; 2020 Mar; 36(3):483-495. PubMed ID: 31834830
[TBL] [Abstract][Full Text] [Related]
30. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
Donkor KN; Selim JH; Waworuntu A; Lewis K
Ann Pharmacother; 2017 Oct; 51(10):840-847. PubMed ID: 28597691
[TBL] [Abstract][Full Text] [Related]
31. Appropriateness of using granulocyte colony-stimulating factor (G-CSF) for primary prophylaxis of febrile neutropenia in solid tumors.
Laali E; Fazli J; Sadighi S; Mohammadi M; Gholami K; Jahangard-Rafsanjani Z
J Oncol Pharm Pract; 2020 Mar; 26(2):428-433. PubMed ID: 31615347
[TBL] [Abstract][Full Text] [Related]
32. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment.
Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
Curr Med Res Opin; 2019 Jun; 35(6):1073-1080. PubMed ID: 30550346
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
Ludwig H; Gascón P; Bokemeyer C; Aapro M; Boccadoro M; Denhaerynck K; Krendyukov A; MacDonald K; Abraham I
Support Care Cancer; 2019 Jun; 27(6):2301-2312. PubMed ID: 30343410
[TBL] [Abstract][Full Text] [Related]
34. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).
Wolff T; Schulz H; Losem C; Reichert D; Hurtz HJ; Sandner R; Harde J; Grebhardt S; Potthoff K; Mueller U; Fietz T
Eur J Haematol; 2019 Feb; 102(2):174-181. PubMed ID: 30347466
[TBL] [Abstract][Full Text] [Related]
35. Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor.
Arvedson T; O'Kelly J; Yang BB
BioDrugs; 2015 Jun; 29(3):185-98. PubMed ID: 25998211
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer.
Mouri A; Kaira K; Shiono A; Yamaguchi O; Murayama Y; Kobayashi K; Kagamu H
Thorac Cancer; 2019 Apr; 10(4):1005-1008. PubMed ID: 30859745
[TBL] [Abstract][Full Text] [Related]
37. [Primary and secondary prophylactic administration of granulocyte-colony stimulating factor(G-CSF)for febrile neutropenia].
Uchino K; Baba E
Gan To Kagaku Ryoho; 2014 Jun; 41(6):691-3. PubMed ID: 25129081
[TBL] [Abstract][Full Text] [Related]
38. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
Liu Z; Doan QV; Malin J; Leonard R
Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473
[TBL] [Abstract][Full Text] [Related]
39. [Use of granulocyte-colony stimulating factor(G-CSF)in patients with cancer at high risk of febrile neutropenia on the basis of high age and complications, recommendations for patients receiving radiotherapy, and adverse events because of G-CSF].
Hanada N; Tanaka S; Takahata T; Sato A
Gan To Kagaku Ryoho; 2014 Jun; 41(6):702-6. PubMed ID: 25129083
[TBL] [Abstract][Full Text] [Related]
40. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
